Bolt Biotherapeutics, Inc. (BOLT)

NASDAQ: BOLT · IEX Real-Time Price · USD
3.96 0.17 (4.49%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap147.65M
Revenue (ttm)231,000
Net Income (ttm)-102.47M
Shares Out37.28M
EPS (ttm)-4.20
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume264,734
Open3.75
Previous Close3.79
Day's Range3.59 - 3.99
52-Week Range3.43 - 43.07
Betan/a
AnalystsStrong Buy
Price Target22.20 (+460.6%)
Earnings DateNov 11, 2021

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to im...

IndustryBiotechnology
IPO DateFeb 5, 2021
Employees65
Stock ExchangeNASDAQ
Ticker SymbolBOLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for BOLT stock is "Strong Buy." The 12-month stock price forecast is 22.20, which is an increase of 460.61% from the latest price.

Price Target
$22.20
(460.61% upside)
Analyst Consensus: Strong Buy

News

3 Biotech Stocks That Sank: Are Any a Bad-News Buy?

At least one of the three could be in store for better news in the future.

Other symbols:AGLERETA
4 weeks ago - The Motley Fool

Why Bolt Biotherapeutics Stock Crashed Today

The company announced disappointing interim data from a phase 1/2 study of its lead cancer program.

1 month ago - The Motley Fool

Bolt Biotherapeutics Reveals Early Data From BDC-1001 Immuno-Oncology Candidate

Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a...

1 month ago - Benzinga

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emer...

Company to continue monotherapy dose-escalation and evaluate weekly dose regimen

1 month ago - GlobeNewsWire

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Co...

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

1 month ago - GlobeNewsWire

Bolt Biotherapeutics Announces Changes to its Board of Directors

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targ...

1 month ago - GlobeNewsWire

Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer ...

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

2 months ago - GlobeNewsWire

Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

–BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021 –Strong cash position of $295.5 million expected t...

2 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer An...

Three SITC presentations highlight the breadth of immuno-oncology strategies from the company's expanding portfolio Three SITC presentations highlight the breadth of immuno-oncology strategies from the ...

3 months ago - GlobeNewsWire

Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with...

REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine t...

4 months ago - GlobeNewsWire

Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the tar...

4 months ago - GlobeNewsWire

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

SAN FRANCISCO and SUZHOU, China, Aug. 26, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

4 months ago - PRNewsWire

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

4 months ago - GlobeNewsWire

Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs

Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?

Other symbols:BEAMGMABMGNXZLAB
6 months ago - PennyStocks

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001...

REDWOOD CITY, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

7 months ago - GlobeNewsWire

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properti...

Bolt's first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human study Bolt's first-in...

9 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the tar...

9 months ago - GlobeNewsWire

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising –

9 months ago - GlobeNewsWire

Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Pu...

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of...

11 months ago - GlobeNewsWire

Bolt Biotherapeutics Prices Upsized Initial Public Offering

REDWOOD CITY, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the pricing of its upsized initial public off...

11 months ago - GlobeNewsWire